FDA Panel Backs Wider Use of Crestor

[Kurt]

http://www.diabetes.org/news-research/news/research-in-the-news/crestorfda-panel-backs-wider-use-of.html

(excerpt)

AstraZeneca's cholesterol-lowering drug rosuvastatin (Crestor) has
received backing from a Food and Drug Administration (FDA) panel for
use by certain patients with healthy cholesterol levels but have other
risks for heart disease.

The drug company sponsored a study of nearly 18,000 patients that
investigated patients who had normal or slightly elevated cholesterol
levels but had increased C-reactive protein (CRP) levels. CRP, a
marker of inflammation, is linked with a risk of developing a number
of diseases, including cardiovascular disease. The study showed that,
compared to a placebo, the drug reduced events including death,
stroke, and heart attack.